SG3 Management’s TG Therapeutics TGTX Stock Holding History

SG3 Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-129,900	Closed	-$1.54M	–	155
2022 Q4	$1.54M	Buy	129,900 +100,000	+334%	+$726K	0.22%	68
2022 Q3	$177K	Hold	29,900	–	–	0.02%	205
2022 Q2	$127K	Sell	29,900 -25,500	-46%	-$159K	0.01%	305
2022 Q1	$527K	Sell	55,400 -27,700	-33%	-$321K	0.01%	585
2021 Q4	$1.58M	Buy	83,100 +20,700	+33%	+$537K	0.03%	383
2021 Q3	$2.08M	Buy	62,400 +22,500	+56%	+$696K	0.06%	291
2021 Q2	$1.55M	Buy	39,900 +29,900	+299%	+$1.17M	0.05%	366
2021 Q1	$482K	Sell	10,000 -149,000	-94%	-$7.16M	0.01%	784
2020 Q4	$8.27M	Buy	159,000 +149,000	+1,490%	+$5.03M	0.16%	127
2020 Q3	$268K	Hold	10,000	–	–	0.01%	684
2020 Q2	$195K	Buy	+10,000	New	+$161K	0.01%	484
2019 Q3	–	Sell	-114,400	Closed	-$990K	–	462
2019 Q2	$990K	Buy	+114,400	New	+$865K	0.11%	160

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SG3 Management's TGTX Position: Q4 2021 in Review

SG3 Management sold out of TG Therapeutics (TGTX) in Q4 2021, closing a stake of 5,371 shares — an estimated $139K sold.

SG3 Management first reported a position in TGTX in Q2 2019 and held it in 5 quarters. The position peaked at $369K in Q2 2021. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

SG3 Management reported no remaining TG Therapeutics position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 5,371 TG Therapeutics shares in Q4 2021, an estimated $139K.
SG3 Management first reported a position in TG Therapeutics in Q2 2019 and held it in 5 quarters.
SG3 Management's TG Therapeutics position peaked at $369K in Q2 2021.
194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.